95 filings
Page 3 of 5
6-K
norsti6
30 Nov 21
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
10:32am
6-K
sm84vs90k
16 Nov 21
Current report (foreign)
2:22pm
6-K
ee4q o68mn8h7w
25 Oct 21
ERYTECH Announces Results from TRYbeCA-1 Phase 3
10:59am
6-K
zvnwq
5 Oct 21
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
12:34pm
6-K
heh2nwh
21 Sep 21
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
9:42am
6-K
1aogsi
20 Sep 21
I.Certification of the Person Responsible for the Half-year Financial Report
1:37pm
6-K
64dfa1e06a t5jpr
30 Jul 21
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
10:09am
6-K
ttmgh8 wbbr11nb
26 Jul 21
Current report (foreign)
11:47am
6-K
jtuea60 o3q0fchu
29 Jun 21
Current report (foreign)
8:18am
6-K
pr3q7fph
26 May 21
Live webcast of the Shareholders’ Meeting
9:55am
6-K
bhqqwhb1k kw9
7 May 21
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
6:13am
6-K
j3g3pp8u9d ya45j
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
6-K
vnj z59uyxv3l
3 May 21
ERYTECH Reports Cash Balance at End of Q1 2021
6:07am
6-K
lye zco8q1igq5
21 Apr 21
ERYTECH Requested a Pre-BLA Meeting with the FDA
8:01am
6-K
xwxzw
19 Apr 21
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of
9:48am
6-K
gd7d0
9 Mar 21
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
9:55am
6-K
gbig 4nnav0coj
8 Feb 21
ERYTECH Announces TRYbeCA-1 Phase 3 Trial
9:15am
6-K
oat72
27 Jan 21
ERYTECH Highlights 2021 Milestones
10:17am
6-K
c2s gn96kb
15 Jan 21
ERYTECH Announces First Patient Enrolled in Eryaspase in First-Line Pancreatic Cancer
12:35pm
6-K
kquly
15 Dec 20
ERYTECH Completes Enrollment in TRYbeCA-1
8:16am